DRNA News 17.19 04/28/2014 05:16:42 Dicerna Pharmaceuticals Inc

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Dicerna Pharmaceuticals Inc (DRNA) 17.19 $DRNA

Dicerna Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire - Fri Apr 18, 3:15PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company's chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 shares of common stock of the Company outside of the Company's stockholder approved equity incentive plan. The grant of this stock option was approved by the compensation committee of the board of directors on April 16, 2014 as an inducement material to Dr. Bhargava entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4). Dr. Bhargava joined the Company as chief medical officer on March 31, 2014. The stock option has an exercise price per share of $16.30, the closing price per share of Company's common stock as reported by NASDAQ on April 16, 2014 and is scheduled to vest over a four-year period, subject to his continued service with the Company. Dr. Bhargava's other compensation information is summarized in a Current Report on Form 8-K previously filed by the Company with the Securities and Exchange Commission.

Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies
Business Wire - Wed Apr 16, 3:15PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the initiation of a Phase 1 dose-escalating clinical study of DCR-MYC, (also known as DCR-M1711), in patients with solid tumors, multiple myeloma, or lymphoma. DCR-MYC, Dicerna's first drug candidate to enter clinical testing, is a Dicer Substrate siRNA (DsiRNA) that targets the driver oncogene MYC, which is central to the growth of many hematologic and solid tumor malignancies. Dicerna is investigating DCR-MYC in a variety of tumor types with the initial focus on hepatocellular carcinoma.

3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 05, 7:10AM CDT
Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them....

Is Biotech in a Bubble? The Bear Case Explained
Chris Ahlstrand, The Motley Fool - Motley Fool - Fri Apr 04, 8:30AM CDT
The rumblings of a biotech bubble are getting louder as the Nasdaq Biotech Index has declined about 14% from its peak of $275.40 on February 25th. The recent volatility is a phenomenon that has not been seen in quite some time in the space. So is...

Dicerna Pharmaceuticals names Dr Pankaj Bhargava as CMO
M2 - Thu Apr 03, 5:02AM CDT
RNAi therapeutics company Dicerna Pharmaceuticals (NasdaqGS RNA) disclosed on Wednesday the addition of Pankaj Bhargava MD, as its chief medical officer.

Dicerna Pharmaceuticals Appoints Dr. Pankaj Bhargava as Chief Medical Officer
Business Wire - Wed Apr 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced the appointment of Pankaj Bhargava, M.D., as Chief Medical Officer. Dr. Bhargava brings to Dicerna more than 15 years of experience in oncology drug development and translational research gained in leading industry and academic institutions. In his role as Chief Medical Officer, he will be responsible for clinical development activities as well as regulatory affairs.

Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014

Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna

Dicerna Announces Fourth Quarter and Full Year 2013 Financial and Operational Results
Business Wire - Thu Mar 27, 3:01PM CDT
---Management to Host Conference Call at 4:30 PM ET-

The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs

Dicerna to Present at Future Leaders in the Biotech Industry Conference on March 28, 2014
Business Wire - Tue Mar 25, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 21st Annual Future Leaders in the Biotech Industry conference on Friday, March 28, 2014 at 2:00 PM ET in New York, NY.

Dicerna to Announce Fourth Quarter 2013 Financial Results and Host Conference Call on March 27, 2014
Business Wire - Mon Mar 24, 3:41PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, will report its fourth quarter 2013 financial results on March 27, 2014. Dicerna will host a conference call and live audio webcast on March 27, 2014 at 4:30 p.m. (ET) to discuss the Company's financial results and provide a general business update.

King Digital, CBS Outdoor Among 10 IPOs Set This Week
at Investor's Business Daily - Mon Mar 24, 3:10PM CDT
King Digital Entertainment leads a slate of 10 IPOs planned for this week, raising the total for the year to 79, up 77% from the year-earlier period. "Candy Crush Saga" developer King Digital is set to start trading on Wednesday. It plans to raise...

Biotechs Tripling at IPO! Sign of Biotech Bubble?
Brian Orelli, The Motley Fool - Motley Fool - Thu Mar 13, 6:24PM CDT
The proverbial biotech IPO window has been open for some time now, but it appears to have grown to the size of an airplane hangar door, allowing almost any biotech to go public at astonishingly high valuations. Ultragenyx Pharmaceutical   doubled...

Dicerna to Present at Two Upcoming Conferences
Business Wire - Thu Mar 06, 8:01AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced that members of the management team will present at two upcoming conferences:

Dicerna to Present at 2014 AsiaTIDES Conference
Business Wire - Mon Feb 24, 8:04AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced that Bob D Brown, PhD, the Company's Chief Scientific Officer and SVP, is scheduled to participate in the 2014 AsiaTIDES Conference being held in Tokyo, Japan February 25-27, 2014. Dr. Brown will chair the main conference plenary session of keynote presentations addressing drug delivery systems for peptides and oligonucleotides; give a presentation titled, "Physical and Chemical Characterization of LNP Formulations of Oligonucleotides vs. Biological Activities;" and participate as a panel member discussing delivery approaches and challenges on Thursday, February 27, 2014.

Global RNAi Drug Delivery Market 2014-2018: Read What's Trending
M2 - Wed Feb 19, 12:15PM CST
Research and Markets (http://www.researchandmarkets.com/research/kv93pj/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018" report to their offering. The analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market. Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp. Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc. Commenting on the report, an analyst from the team said: Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. For more information visit http://www.researchandmarkets.com/research/kv..._rnai_drug About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Dicerna to Present at 2014 Leerink Global Healthcare Conference on February 13th
Business Wire - Fri Feb 07, 8:05AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company's President and CEO, is scheduled to present at the 2014 Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 1:00 PM ET in New York, NY.

Dicerna Announces Participation in Panel on RNAi Therapeutics at 16th Annual BIO CEO and Investor Conference on February 10th
Business Wire - Wed Feb 05, 8:05AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leader in the development of RNAi-based therapeutics, today announced its participation in a panel discussion on RNAi therapeutics at the 16th Annual BIO CEO & Investor Conference. Douglas M. Fambrough, PhD, the company's President and CEO, is scheduled to take part in a Therapeutic Workshop entitled: "Delivering the [RNAi] Goods" to be held on Monday, February 10th, at 10:30 a.m. Eastern Standard Time.

Form 4: Update Filing for Dicerna Pharmaceuticals Inc (DRNA)
Vickers Stock Research - Wed Feb 05, 5:57AM CST
Mt. Laurel, NJ - February 5, 2013 - PHH Corporation (NYSE: PHH) ("PHH" or the "Company" announced today that Kathryn M. Ruggieri has been named Senior Vice President and Chief Human Resources Officer. Ruggieri has served as Interim Chief Human Resources Officer since September 2012.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 50

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 168

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 202

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 29

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 153

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Ohmyhome Prepares to Share Exciting Q3 2024 Growth Insights

Updated Category News Views 84

Ohmyhome Set to Unveil Q3 2024 Growth Insights As a leading property technology platform, Ohmyhome Ltd. (NASDAQ: OMH) has established itself as a prominent player in the real estate market. The company specializes in offering comprehensive solutions ranging from brokerage, renovation, and management services for properties in the region. As consumers increasingly look for...

Continue Reading
Innovative Partnership Between TotalEnergies and Emerson Energizes Industrial Data Solutions

Updated Category News Views 344

Transforming Industrial Data Management TotalEnergies and Emerson are uniting to implement extensive industrial data collection solutions across TotalEnergies' operational landscape. This exciting partnership aims to harness continuous and real-time data collection to significantly enhance operational efficiency, energy utilization, and environmental performance at...

Continue Reading
Doré Copper and Cygnus Metals Forge New Mineral Giant Together

Updated Category News Views 114

Doré Copper and Cygnus Metals Join Forces for a Stronger Future Doré Copper Mining Corp. (TSXV: DCMC; OTCQB: DRCMF; FRA: DCM) is thrilled to announce an exciting development. The company has entered into a definitive arrangement agreement with Cygnus Metals Limited (ASX: CY5) to merge their businesses. This is not just any merger; it's a merger of equals that aims to...

Continue Reading
G Mining Ventures Unveils Key Corporate Developments

Updated Category News Views 132

G Mining Ventures Unveils Key Corporate Developments G Mining Ventures Corp. has been making headlines as it continues to expand its influence in the mining industry. The company is dedicated to innovating its strategies while navigating the complexities of market dynamics. By focusing on sustainable practices and operational efficiency, G Mining Ventures aims to enhance...

Continue Reading
Neutrinos Launches Innovative Suite to Transform Insurance Underwriting

Updated Category News Views 489

Neutrinos Launches Innovative Suite for Underwriting Automation In a transformative leap forward for the insurance industry, Neutrinos has introduced its Underwriting Automation Suite, tailored specifically for life, annuities, and health insurance. This cutting-edge tool aims to streamline underwriting workflows, enhance risk assessments, and ultimately elevate...

Continue Reading